Cancer NetworkOriginal article
<![CDATA[Iberdomide Triplet Improves MRD-Negative CRs in R/R Multiple Myeloma]]>
Phase 3positiveIberdomideDaratumumabDexamethasonePositive
AI Analysis
Summary
The Phase 3 EXCALIBER-RRMM trial demonstrated that iberdomide combined with daratumumab and dexamethasone improves MRD-negative complete responses in relapsed/refractory multiple myeloma, supporting its use as a new standard of care.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Iberdomide triplet improves MRD-negative complete responses in relapsed/refractory multiple myeloma; supports new standard of care
Importance:7/10
Sentiment:
0.75
Phase 3Multiple MyelomaClinical TrialPositive DataOncology
Related Companies
Read the original article
Published by Cancer Network on September 26, 2026 8:00 PM